Navigation Links
Avastin Won't Extend Breast Cancer Survival: Study

By Kathleen Doheny
HealthDay Reporter

FRIDAY, Dec. 7 (HealthDay News) -- The drug Avastin (bevacizumab), when added to chemotherapy, does not improve disease-free survival in patients with triple-negative breast cancer any better than chemo alone, new research finds.

"Therefore, sadly for patients, we have nothing extra to add to chemotherapy for early, triple-negative breast cancer," Dr. David Cameron, a professor of oncology at Edinburgh University in Scotland, said in a news release from the American Association for Cancer Research.

He was scheduled to present the findings Friday at the 2012 San Antonio Breast Cancer Symposium.

Previous studies of Avastin had found benefit. However, in 2011, the U.S. Food and Drug Administration revoked approval of the drug for late-stage breast cancer, citing risks -- such as heart failure and severe high blood pressure -- that outweigh the benefits. The drug may still be used off-label, with doctors prescribing it to patients if they think that patient could be helped.

This new study signals the death of the drug for breast cancer, although it is helpful in other cancers, said Dr. Joanne Mortimer, director of Women's Cancer Programs for the City of Hope Comprehensive Cancer Center in Duarte, Calif. She reviewed the new findings.

Another physician took a different view, saying others should consider continuing research on the drug. "We have all seen some success stories with the drug, and Avastin may be a drug that works in only a select few," said Dr. Stephanie Bernik, chief of surgical oncology at Lenox Hill Hospital in New York City.

Avastin is marketed by Genentech. Swiss drugmaker Hoffmann-La Roche, which acquired Genentech, sponsored the study.

For the new study, researchers randomly assigned nearly 2,600 patients with triple-negative operable primary invasive breast cancer to four or more cycles of chemotherapy. They used either an anthracycline-based or taxane-based chemo drug. One group also received a year of Avastin therapy.

Triple-negative breast cancer refers to those tumors that do not have estrogen or progesterone receptors or express the HER2/neu gene.

The researchers followed the women to see if the Avastin made a difference in disease-free survival. At a median follow-up of 32 months, no significant improvement occurred by adding Avastin.

Among those who received chemo alone, 107 died during the follow-up period, compared with 93 deaths in the group getting chemo plus Avastin, the investigators found.

Those in the Avastin group were more likely than the chemo-alone group to have problems such as severe high blood pressure and congestive heart failure.

The drug is effective in other cancers, Mortimer said. "It's a very important drug for lung, [gastrointestinal] and kidney cancers," she explained.

The drug is still listed in the recommendations for breast cancer treatment by the National Comprehensive Cancer Network. The not-for-profit is an alliance of 21 major international cancer centers, including City of Hope.

Health insurers turn to the recommendations when deciding which drugs to cover. Avastin is costly, about $112,000 a year for breast cancer patients.

Because this study was presented at a medical meeting, the data and conclusions should be viewed as preliminary until published in a peer-reviewed journal.

More information

To learn more about breast cancer, visit the American Cancer Society.

SOURCES: Joanne Mortimer, M.D., director, Women's Cancer Program, City of Hope Comprehensive Cancer Center, Duarte, Calif.; Stephanie Bernik, M.D., chief, surgical oncology, Lenox Hill Hospital, New York City; Cancer Therapy & Research Center-American Association for Cancer Research, news release; Dec. 7, 2012, presentation, 2012 San Antonio Breast Cancer Symposium

Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Interpreting the Avastin-Lucentis study for persons with macular degeneration
2. Avastin No Benefit to Older Lung Cancer Patients: Study
3. More Fake Avastin Found in U.S., FDA Says
4. No Benefit Seen in Extending Herceptin for Breast Cancer
5. Chemo May Extend Survival After Breast Cancers Return
6. NIH study finds leisure-time physical activity extends life expectancy as much as 4.5 years
7. Study: Repeated surgeries appear to extend life of patients with deadliest of brain cancers
8. Supportive Spouse May Extend Cancer Survival
9. Precautions for tick-borne disease extend beyond Lyme
10. New Drug Appears to Extend Survival in Advanced Prostate Cancer Patients
11. Golden age of prostate cancer treatment hailed as fourth drug in 2 years extends life
Post Your Comments:
Related Image:
Avastin Won't Extend Breast Cancer Survival: Study
(Date:11/26/2015)... ... 2015 , ... PRMA Plastic Surgery is updating their record books yet again ... free flap breast reconstruction surgery! , “What an accomplishment for the PRMA team, says ... and it’s an honor to have served all of these women.” , PRMA is ...
(Date:11/26/2015)... ... November 26, 2015 , ... Indosoft Inc., developer and distributor of the ... to improve system efficiency and reliability. , The new Q-Suite 6 platform is based ... system avoids locking itself into a specific piece of software for many key components ...
(Date:11/25/2015)... ... November 25, 2015 , ... Finnleo, a leader in ... on several models of traditional and far-infrared saunas. , For traditional saunas, ... the most traditional Finnish sauna wood, and Finnleo uses only European Grade A Nordic ...
(Date:11/25/2015)... ... November 26, 2015 , ... Ministers, senior government ... ANDI Pan African Centres of Excellence, and public R&D institutions, civil societies and ... opening of the 5th African Network for Drugs and Diagnostics Innovation, ANDI, Stakeholders ...
(Date:11/25/2015)... FL (PRWEB) , ... November 25, 2015 , ... ... center, is encouraging people across the country to celebrate their sobriety and show ... people to post “before and after” photos this Thanksgiving with the hashtag #FacesOfGratitude ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... 2015 --> ... blends immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer. ... immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer.   ... immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer.   ... that immunotherapy can be efficiently combined with photodynamic therapy ...
(Date:11/26/2015)... --> --> Juntendo University ... contrast weighting of MRI for patients with Multiple Sclerosis ... agreement with SyntheticMR in order to use SyMRI in clinical ... to generate multiple contrast images from a single scan and ... making it possible to both fine tune images and recreate ...
(Date:11/26/2015)... SAN FRANCISCO , November 26, 2015 ... 1.82 billion by 2022, according to a new report by ... as Chronic Kidney Disease (CKD) which demands kidney transplantation is ... convenient and cost effective substitute for organ transplantation. --> ... 1.82 billion by 2022, according to a new report by ...
Breaking Medicine Technology: